Showing results (981-990 of 9,404) with videos related to
Sort By:
Pageof 941
Clinical Pharmacology and Therapeutics|April 4, 2006
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolamTeijo I Saari, Kari Laine, Kari Leino, et al.Clinical Pharmacology and Therapeutics|December 1, 1976
Interaction between antipyrine and aminopyrineE S Vesell, G T Passananti, G W HepnerClinical Pharmacology and Therapeutics|January 3, 2008
Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trialK Mörike, K T Kivistö, E Schaeffeler, et al.Clinical Pharmacology and Therapeutics|January 3, 2008
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humansY Yamasaki, I Ieiri, H Kusuhara, et al.Clinical Pharmacology and Therapeutics|January 10, 2008
Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studiesM Natekar, V Mahajan, A Satra, et al.Clinical Pharmacology and Therapeutics|January 10, 2008
The Biomarkers Consortium: on the critical path of drug discoveryC A AltarClinical Pharmacology and Therapeutics|January 10, 2008
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypesM-S Wen, Mtm Lee, J-J Chen, et al.Clinical Pharmacology and Therapeutics|February 10, 1999
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltrationI Tegeder, F Neumann, F Bremer, et al.Clinical Pharmacology and Therapeutics|September 1, 1976
Colestipol in familial type II hyperlipoproteinemia: a three-year trialC Harvengt, J P DesagerClinical Pharmacology and Therapeutics|February 7, 2008
Perspectives from the clinic: will the average physician embrace personalized medicine?H Levy, J H YoungPageof 941